NL-OMON26844招募中不适用
GAP-trial: General Anesthesia exposure and neurodevelopmental outcome in Pediatric
Emma Children’s Hospital, Amsterdam UMC.0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria: age 12 months (± four weeks) with a history of general anesthesia exposure (patient group) or without a history of general anesthesia (healthy controls)
排除标准
- •Children with comorbid conditions affecting structure and/or function of the central nervous system (e.g. premature birth) will be excluded from participation in this study.
研究者
相似试验
进行中（未招募）
不适用
Ensayo clínico para evaluar el efecto sobre la grasa subcutánea del cambio de EFV por LPV/r en pacientes infectados por VIH que desarrollaron lipoatrofia que sigue siendo clínicamente evidente a pesar del tratamiento con efavirenz y una combinación a dosis fija de análogos de nucleósidos no timidínicos.EUCTR2009-010611-33-ESFundació clinic per a la Recerca biomèdica
尚未招募
2 期
clinical study on the effect of Gudapippali Ghruta and Shatavari Ghruta in the management of Parinama shoola(Acid Peptic Disorders ) and to study the role of H.Pylori in its manifastation.â??CTRI/2017/08/009316Rajiv Gandhi University of Health Sciences
尚未招募
不适用
A human pilot study to investigate the effect of daily consumption of gold kiwifruit for 2 weeks on transcriptomic changes in buccal epithelial cells and blood in healthy males.ACTRN12620001359921Plant & Food Research6
进行中（未招募）
1 期
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin’s LymphomaRelapsed or Refractory, Follicular Non-Hodgkin’s LymphomaMedDRA version: 8.1Level: LLTClassification code 10029627Term: Non-Hodgkin's lymphoma unspecified histology intermediate grade refractoryEUCTR2005-003836-22-SKBiogen Idec Ltd.700
进行中（未招募）
1 期
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin’s LymphomaRelapsed or Refractory, Follicular Non-Hodgkin’s LymphomaMedDRA version: 8.1Level: LLTClassification code 10029627Term: Non-Hodgkin's lymphoma unspecified histology intermediate grade refractoryEUCTR2005-003836-22-GBBiogen Idec Ltd.742